Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia
By Australian Hospital + Healthcare Bulletin Staff
Tuesday, 17 October, 2017
October 1st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the treatment of adults with schizophrenia. REXULTI works on three neurotransmitter systems: serotonin, dopamine and noradrenaline.1
The efficacy and safety of REXULTI have been demonstrated in two short-term studies and one long-term maintenance trial.1
REXULTI tablets are taken once daily and come in dose strengths of 1 mg, 2 mg, 3 mg and 4 mg with a recommended target dose of 2-4 mg/day.
Lundbeck Australia and Otsuka Australia Pharmaceutical are dedicated to bringing innovative new medicines to Australians with psychiatric disorders.
Please review the REXULTI Approved Product Information before prescribing. Product information is available by calling Lundbeck on 1300 721 277 or click here.
October 1st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the...
The ACIPC International Conference is Australasia's pre-eminent conference for Infection...
Environmental cleaning and disinfection is a unique challenge.